Emily Kaiser Maharjan, Assistant Managing Editor

Two novel, dropless technologies for keratoconus and dry eye disease make major advances with more to come later in 2023.

The VEGA-2 pivotal trial is investigating Nyxol alone and Nyxol with adjunctive low-dose pilocarpine therapy for the treatment of presbyopia.

The patented AR lens coating creates thinner, stronger lenses than the alternative, and is now available to patients who love Transitions lenses.

The lens giant pairs precision vision of freeform-optimized lenses with the cost benefit of standard single vision lenses.

In the second deal between Harrow and Novartis, the former is expected to add 5 ophthalmic products to its portfolio.

Marc R. Bloomenstein, OD, FAAO, shares key takeaways from his EyeCon 2022 presentation, "Advances in presbyopia."

Ruth Shoge, OD, MPH, FAAO, shares key takeaways from her EyeCon 2022 presentation, "Diversity in practice, creating an inclusive and equitable workspace."

Justin Schweitzer, OD, gives a brief overview of his EyeCon 2022 presentations, reflecting on pipeline advancements made in optometry in 2022.

Adam Ramsey, OD, shares key takeaways from his EyeCon 2022 presentation, "Advances in industry innovations to improve your practice."

Mile Brujic, OD, FAAO, shares key takeaways from his EyeCon 2022 presentation, "Advances in presbyopia."

Lyndon Jones, BSc, PhD, DSc, FCAHS, FCOptom, DipCLP, DipOrth, FAAO, FIACLE, FBCLA , shares key takeaways from his EyeCon 2022 presentation, "Advances in presbyopia."

As the first and only preservative-free formulation of latanoprost, IYUZEH 0.005% is approved to reduce IOP in patients with open-angle glaucoma or ocular hypertension.

Adam Ramsey, OD, shares key takeaways from his presentation on diversity, equity, and inclusion in you optometry practice, which he presented during EyeCon 2022.

The preservative-free, multi-dose contact lens rehydrating drops are expected to hit the market in early 2023.

The submission is supported by positive phase 3 data, which shows quick reversal of dilation and favorable safety and tolerability.

Rob Sambursky, MD, president of Verséa Ophthalmics, sat down with David Hutton of Ophthalmology Times to discuss 3 major developments in the company pipeline.

The #GlassesOn campaign promotes the benefits of eyewear for kids and invites support for the non-profit through Giving Tuesday on November 29th.

Ocuphire seeks to develop and commercialize Nyxol for the reversal of mydriasis, presbyopia and night vision disturbances.

The submission of 24-month efficacy data from DERBY and OAKS is classified as a Major Amendment to the New Drug Application, which delays the PDUFA target action date until February 2023.